Chronic Myeloid Leukemia‎ News and Features

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.

Nilotinib for CML Associated With Improved Quality of Life

Nilotinib for CML Associated With Improved Quality of Life

Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.

Adding Pioglitazone to Imatinib May Improve Response in CML

Adding Pioglitazone to Imatinib May Improve Response in CML

Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs